Rice-derived Recombinant Human Serum Albumin for the Treatment of Hypoalbuminemia After Hepatectomy: A Prospective, Single-Arm, Exploratory Clinical Trial

Inclusion Criteria: * Able to understand and willing to sign the informed consent form. * Male or female; age ≥18 years and ≤80 years. * Planned for or has undergone hepatectomy. * Developed postoperative hypoalbuminemia, defined as serum albumin ≤30 g/L . Exclusion Criteria: * Known hypersensitivity to the active ingredient or any excipient of the investigational drug * Complicated with any of the following diseases or conditions: severe renal disease requiring hemodialysis, active upper gastrointestinal bleeding, hepatic encephalopathy Grade III or IV. * Pregnant or lactating women. * HIV positive. * Heart failure classified as Stage C or D according to ACCF/AHA criteria. * History of organ transplantation. * Mental status that prevents the participant from understanding the nature, scope, and consequences of the study. * Any clinical condition that the investigator considers makes the trial participant unsuitable for participation in the trial.